Summary: Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLEM trial.

Summary: The aim of this observational study was to compare the effectiveness of sodium-glucose co-transporter 2 inhibitor (SGLT2i) and empagliflozin treatment on left ventricular (LV) dysfunction between early and advanced diabetes mellitus-related cardiomyopathy (DMCMP).

Summary: The safety outcomes of sodium-glucose cotransporter 2 inhibitors in patients with different renal function: A systematic review and meta-analysis.

Summary: This trial evaluated the use of empagliflozin to treat patients with syndrome of inappropriate antidiuresis (SIAD).

Summary: The study compared the outcomes of ertugliflozin alone or with other antihyperglycaemic agents for patients with type 2 diabetes.